SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors reduce cardiovascular mortality in diabetes through pleiotropic mechanisms including antioxidant effects, anti-inflammatory properties, improved endothelial function, and beneficial NO signaling.
Beyond glucose controlSGLT2i and GLP-1RA reduce cardiovascular mortality through direct antioxidant, anti-inflammatory, and endothelial protective effects—not just by lowering blood sugar
What the researchers found
All three drug classes: antioxidant, anti-inflammatory, endothelial protective. GLP-1RAs + SGLT2i: reduce CV mortality, protect against ischemia/reperfusion, slow HF progression. Mechanisms: oxidative stress reduction, inflammation suppression, NO signaling improvement, epigenetic/microbiotic pathway modulation.
Why it matters
Understanding WHY these drugs protect the heart helps optimize their use—benefits are not just from glucose control but from direct organ protection through anti-inflammatory and antioxidant mechanisms.
How the study worked
Comprehensive narrative review comparing mechanisms of cardiovascular protection across DPP-4i, GLP-1RA, and SGLT2i drug classes.
What this study cannot tell us
Narrative review. Mechanistic evidence largely from preclinical studies. Direct comparisons between classes limited. Not all patients may derive equal cardiovascular benefit.
How to read the evidence
Comprehensive narrative review integrating clinical trial outcomes with mechanistic evidence.
When this study was published
Published in 2025.
The bigger picture
The shift from glucose-centric to organ-protective diabetes treatment represents one of the biggest paradigm changes in modern medicine. These drugs are fundamentally cardioprotective agents that also control blood sugar.
Questions still open
- Which antioxidant/anti-inflammatory mechanisms are most clinically important?
- Should these drugs be prescribed to non-diabetic patients for cardiovascular protection?
- Can combining all three classes provide additive organ protection?
Common questions
How do diabetes drugs protect the heart?
Should non-diabetic people take these drugs for heart protection?
Read the original research
Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.
Pharmacological reviews, 77(5), 100082
Citation
Steven, Sebastian; Kuntic, Marin; Münzel, Thomas; Daiber, Andreas. (2025). Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.. Pharmacological reviews, 77(5), 100082. https://doi.org/10.1016/j.pharmr.2025.100082